NasdaqGS:CMPSBiotechs
Why COMPASS Pathways (CMPS) Is Up 21.3% After Phase 3 Psilocybin Win And $150M Equity Raise
Earlier this week, COMPASS Pathways plc reported highly statistically significant and clinically meaningful positive Phase 3 results for its psilocybin-based therapy COMP360 in treatment-resistant depression, alongside generally well-tolerated safety data and a request for an FDA meeting on a potential rolling submission.
The company paired this clinical milestone with a US$150,000,000 follow-on equity offering, underlining how pivotal COMP360 has become to its future plans.
We’ll now look...